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Abstract. Apoptosis plays a crucial role in tissue homeostasis, development and many diseases. The
relevance of Apaf1, the molecular core of apoptosome, has been underlined in mitochondria-dependent
apoptosis, which according to a growing body of evidence, is involved in various pathologies where the
equilibrium of life-and-death is dysregulated, such as heart attack, stroke, liver failure, cancer and
autoimmune diseases. Consequently, great interest has emerged in devising therapeutic strategies for
regulating the key molecules involved in the life-and-death decision. Here we review recent progress in
apoptosis-based pharmacological therapies and, in particular, we point out a possible role of the
apoptosome as an emerging and promising pharmacological target.
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INTRODUCTION
Apoptosis is an evolutionarily conserved form of cell
death which regulates development and tissue homeostasis
and also plays a pivotal role in the cytotoxic activity of most
chemotherapeutic drugs and in the response to pathogens.
Apoptosis is characterized by morphological changes of the
cell such as chromatin condensation, membrane blebbing,
cell shrinkage and ﬁnally cellular fragmentation in vesicular
bodies subsequently taken up by macrophages (1).
In humans about a hundred thousand cells are produced
every second by mitosis and a similar number of cells die by
apoptosis; this physiological process is essential for the
maintenance of tissue homeostasis and serves to remove
extraneous or dangerous cells.
An inappropriately low rate of apoptosis can promote
the survival and accumulation of abnormal cells which can
contribute to cancer development or autoimmune disease.
Conversely, many acute pathologies such as heart attack,
stroke and liver failure are associated with abrupt cell death
of whole tissue areas (myocardium, central nervous system,
liver), whereas many neurodegenerative diseases are the
result of a more slowly progressive neuronal death.
It is evident that apoptotic defects and/or aberrations in
apoptotic responses to death signals can contribute to various
humandiseaseswherethereisanexcessiveordeﬁcientcelldeath.
The current review, besides providing an overview of the
apoptotic machinery and the apoptosome structure, will focus
on the recent progress of apoptosis-based therapies, particu-
lar attention being paid to new and promising therapeutical
tools which can modulate the apoptosome function.
THE APOPTOTIC MACHINERY
As outlined above, apoptosis is a cellular process which
leads to cytoskeletal and nuclear proteolytic digestion. These
typical features are the consequence of activation of a family
of proteases called caspases, which are produced as zymo-
genes. Based on the activation order in cell death pathways,
caspases are divided into two major groups: executioner
caspases and initiator caspases (2). The executioner caspases,
caspase-3, -6 and -7 in mammals, cleave selected substrates to
produce the typical alteration changes associated with
apoptosis. The executioner caspases are activated by initiator
caspases, including caspase-8, -9 and -10. By examining the
patterns of caspase activation following different apoptotic
stimuli, two main pathways have emerged: the death receptor
pathway (extrinsic pathway) and the mitochondrial pathway
(intrinsic pathway; 3,4) (Fig. 1).
The extrinsic apoptotic program, which often does not
require mitochondria, is activated by death receptor stimula-
tion. All death receptors are characterized by an intracellular
motif called the death domain (DD). Upon stimulation, the
death receptors interact via their DD with the DD of adaptor
proteins such as Fas-Associated Death Domain (FADD).
The adaptor proteins also contain a second interaction motif,
the death effector domain (DED), which facilitates their
binding to the initiator caspase-8 (or caspase-10) to form the
death-inducing signalling complex (DISC). DISC formation
activates caspase-8 (or caspase-10) (5) which subsequently
cleaves and activates caspase-3. In some cell types the
procaspase-3 cleavage by DISC formation is associated to
mitochondrial mediated cell death. In this case the mito-
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cleavage of Bid, a pro-apoptotic member of the Bcl-2 family.
Once cleaved, truncated Bid (t-Bid) translocates to the
mitochondria where it induces the cytochrome c release, the
ﬁrst step of the intrinsic pathway.
Many death signals originating from cellular stress
activate an intrinsic apoptotic program which is mediated
by the mitochondria. The mitochondria outer membrane
permeabilization (MOMP) is an important step in the
intrinsic pathway. Permeabilization mechanisms are contro-
versial, the two principal hypotheses involving the MTP
(Membrane Transition Permeabilization) and the Bcl-2
family proteins (6). The involvement of the MTP in apoptosis
is debatable, as it seems more speciﬁc for necrosis (7). Thus
the major role in membrane permeabilization seems to be
carried out by Bcl-2 family members, even if their mechanism
of action is far from clear. These proteins are characterized
by the presence of one or more Bcl-2 homology (BH)
domains. They are divided into: pro- (Bax, Bak, etc) and
anti-apoptotic (Bcl-2, Bcl-XL, etc) proteins. Pro-apoptotic
members are further divided into two subgroups: the BH3-
only proteins and the proteins which possess BH1, BH2 and
BH3 domains (8). Bax and Bak, as a consequence of
apoptotic stimuli, are subject to conformational changes and
oligomerization (9) and they cause membrane permeabiliza-
tion by destabilizing the lipid bilayer, creating pores or
interacting with channels (10). Bax and Bak are counteracted
by Bcl-2 anti-apoptotic members, which are present in the
outer membrane. In this regulation the BH3-only proteins
have an important role (11). Several models of Bcl-2
proteins_ function and regulation have been proposed and
they are mentioned later on when describing the BH3
mimetics.
The result of permeabilization is the release, into the
cytoplasm, of cytochrome c, which, in the presence of dATP,
induces the formation of the Apaf1-containing macromolec-
ular complex called the apoptosome. This complex, in turn,
binds and activates procaspase-9. Mature caspase-9 remains
bound to the apoptosome, recruiting and activating execu-
tioner caspase-3 and/or caspase-7.
The absence of the apoptosome inhibits the completion of
the apoptotic process in many systems. Under these conditions
cells which had been induced to death cannot complete the
apoptotic program even though they show some early
biochemical modiﬁcations typical of programmed cell death
which might affect cell survival such as the release of the
cytochrome c from mitochondria. Are these modiﬁcations
irreversible or can cells with apoptosome impairment triggered
to apoptosis be metabolically active and so have the capacity
to recover? What is the point-of-no-return in apoptosis? This
is a frequently addressed question not yet clariﬁed.
The release of the cytochrome c has often been
considered the point-of-no-return in cell death since cyto-
chrome c is part of the mitochondrial respiratory chain which
transports electrons from complex III to complex IV and is
responsible for the generation of the mitochondrial mem-
brane potential (DYm). DYm is needed for various functions
including the production of ATP via oxidative phosphoryla-
tion. Permeabilization of the mitochondrial outer membrane
and release of cytochrome c should therefore, in principle,
have a strong impact on mitochondrial function and behav-
iour because the proton gradient generated by the electron
transport chain should be impaired.
However, this point is still controversial. Some reports
show that release of cytochrome c and disruption of DYm will
kill the cell in a caspase-independent way if downstream
apoptotic effects are blocked. In fact, in cells lacking caspase-
9 or Apaf1 death is delayed but still inevitable and such cells
are, in effect, considered Bzombies,^ i.e. severely impaired
cells which cannot be deﬁned as living normal cells (12). By
contrast, other studies ﬁnd that cytochrome c released and
diffused in the cytoplasm is able to maintain DYm and ATP
generation in caspase-inhibited cells and in Apaf1
j/j cells.
This suggests that mitochondrial recovery and cell survival
are possible after the release of cytochrome c which is not the
point of-no-return (13,14).
More recently, the Doug R. Green laboratory demon-
strated that in other cell systems, such as the widely used
HeLa cells, this may also be the case. They have identiﬁed
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a
critical regulator of caspase-independent cell death which
may follow caspase inhibition. In particular, they have shown
that GAPDH-expressing cells preserved their clonogenic
potential following loss of mitochondrial membrane poten-
tial, provided that caspase activation was blocked. This might
Fig. 1. Apoptosis signalling pathways. Two important pathways of
caspase activation exist in mammalian cells, one involving death
receptor and the other involving mitochondria (see also text); (Y
activation; ; inhibition). The extrinsic cell death pathway (dotted
line) is mediated by death receptors (the best studied death receptor
is Fas).The binding of Fas ligand (FasL) leads to receptor activation.
The Fas receptor contains a death domain (DD) in its cytoplasmic
region which interacts with the adaptor protein (FADD), forming the
DISC (Death-Inducing Signalling Complex). DISC formation results
in the activation of caspase-8,-10 which in turn will activate
downstream effector caspase (caspase-3,-7). In the mitochondrial
pathway (continuous line), which is initiated by multiple forms of
cellular stress, Bax and Bak are activated at mitochondria. Also, Bid
(activated by caspase-8 cleaveage in extrinsic cell death pathway)
activates Bax and Bak to mediate the release of cytochrome c in the
cytosol. Cytochrome c and dATP trigger the assembly of the Apaf1-
apoptosome, which recruits and activates caspase-9. This, in turn,
cleaves and activates caspase-3. The activation of caspase-3, -7 is
antagonized by IAPs, which in turn can be inhibited by Smac/
DIABLO and Omi/HtrA2.
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modulation of apoptosome functions (15).
APOPTOSOME FORMATION AND STRUCTURE
Apaf1 is characterized by three domains: the N-terminal
CARD (Caspase-Recruitment Domain), the central NBD
(Nucleotide Binding Domain) and the C-terminal WD-40
repeats. The CARD interacts with the CARD domain of
caspase-9; the NBD binds alternatively dATP/ATP. CARD
domain and NBD domain are involved in oligomerization of
Apaf1 in presence of cytochrome c and dATP. The C-
terminal is involved in cytochrome c binding. It remains
unknown if other molecules can interact with this region.
Apaf1 exists as a monomer in an inactive conformation,
where the CARD interacts with the C-terminal so impeding
the binding of procaspase-9. Cytochrome c, released from
mitochondria, binds to WD-40 repeats thus inducing hydro-
lysis of dATP to dADP and the exchange of dADP with
cytosolic dATP (16). When dATP binds to Apaf1 it causes a
conformational change which allows the binding of procas-
pase-9. After activation, caspase-9 remains associated to the
apoptosome (17).
The modalities of caspase-9 activation are still unclear,
although some hypotheses, recently reviewed by Bao and Shi
(18), have been formulated to explain them. Brieﬂy, accord-
ing to the Binduced proximity^ model, caspase-9 monomers
are able to activate themselves, when they are near each
other (19). This model, based on experiments on caspase-
8( 20) and then extended to the other initiator caspases (19),
does not reveal the mechanical aspects of the activation and
it has been reinterpreted in two other models (21).
According to the Bproximity driven dimerization^ mod-
el, apoptosome recruits procaspase-9 monomers, promoting
dimerization and hence activation. This is based on the
observation that procaspases are inactive as monomers,
whereas dimers are active (22). A recent work (23) seems
to conﬁrm this model; in fact, a reconstituted mini-apopto-
some activates caspase-9 by a second order process compat-
ible with the dimer-driven process. By contrast, the Binduced
conformation^ model states that apoptosome, causing con-
formational changes in caspase-9, has an active role in its
activation. This is based on the observation that an engi-
neered dimeric caspase-9 has a qualitatively different activity
from the caspase-9 activated by apoptosome (24). Moreover,
a recent study shows the importance of apoptosome in
increasing caspase-9 afﬁnity for procaspase-3 (25).
Several studies based on electron cryo-microscopy have
been carried out to identify the apoptosome structure. They
have revealed a wheel-like complex made up of seven Apaf1
molecules (26,27). According to these models, the CARD
domains are located at the central hub, where the procas-
pase-9 interacts, whereas the WD-40 repeats form Y-shaped
tails at the end of the spokes. In addition, recent studies
based on computer simulation (28) and mathematical models
(29) have been made to clarify the apoptosome structure and
the mechanical aspects of assembly, respectively. All these
efforts are important, because a deeper knowledge of the
apotosome structure can be used to identify binding sites as
potential targets for drug design.
APOPTOSOME REGULATION
Many factors are involved in apoptosome formation and
regulation in physiological conditions. Heat shock proteins
are involved in apoptosis inhibition, acting at several steps of
both extrinsic and intrinsic pathways. In particular in the
intrinsic pathway they are involved both at mitochondrial
and at the apoptosome levels (30). Heat shock protein 90 and
70, induced by several toxic stimuli, prevent apoptosome
formation binding to Apaf1 and inhibiting its oligomerization
(31, 32). However, Hsp70_s direct role in apoptosome
inhibition is challenged by the observation that this interac-
tion might be an artifact, and that it has no effect in cells
where cytochrome c has been released. Thus, Hsp70 might
act only upstream of the mitochondria (33).
TUCAN (Tumor-Up-regulated CARD-containing An-
tagonist of caspase-9) and its isoform TUCAN-54, bind
procaspase-9 by their CARD domain, thus inhibiting the
interaction with Apaf1 (34, 35).
IAPs(theInhibitorof ApoptosisProteins), other proteins
involved in apoptosome regulation, are characterized by the
presence of the BIR (Baculoviral IAP Repeat) domain, that
allows them to bind caspases. They are sub-divided into three
classes: the ﬁrst class is characterized by the presence of BIR
domains and the Ring ﬁnger motif (XIAP, ML-IAP, cIAP1,
cIAP2, etc.); the second class has three BIR domains (NAIP);
the third has one BIR domain (survivin) (36).
XIAP (X-linked Inhibitor of Apoptosis Protein) binds
active caspase-3 and caspase-7 through the BIR2 domain,
whereas caspase-9 is bound, in its inactive monomeric form,
by the third BIR domain (37). The Ring domain, which has
E3 ubitiquin ligase activity, promotes ubiquitination and
subsequent degradation of caspase-3 and -9 (37).
There are contrasting data on IAPs role. In fact some
studies mainly based on GST-fusion proteins demonstrated
that they bind and inhibit caspases (38, 39). However, recent
experiments have revealed that many IAPs are not able to
inhibit caspases in physiological concentrations (40); in
particular cIAP1 and cIAP2 are able to bind, but not to
inhibit caspases, probably because of the lack of important
sites for caspase inhibition (41). The role of survivin in the
direct inhibition of caspases is questionable, too (42,43).
Thus, as of now XIAP seems the only direct caspase inhibitor
among the IAPs (44). It has been proposed that IAPs could
have a role in interacting with XIAP antagonists, so leading
free XIAP to take on its inhibiting role, or in causing
degradation of caspases or XIAP antagonists by ubiquitina-
tion. It has been also discovered by point mutations that
XIAP is able to inhibit apoptosis when it loses the ability to
bind caspase-3 and caspase-9 but retains its ability to bind the
antagonist DIABLO (45). Thus the interaction with antago-
nists seem to have a relevant role in IAPs function.
Inhibitors of IAPs also exist. For example, Smac/
DIABLO and Omi/HtrA2, released from intermembrane
space when mitochondria are damaged, are able to interact
with and inhibit IAPs (46). XIAP is inhibited by both Smac/
DIABLO and Omi/HtrA2.
PHAPI, also known as Mapmodulin (Putative HLA-
DR-Associated Protein), is a pro-apoptotic factor. Previous
studies have shown its role in increasing caspase-3 activity
(47). Recent studies have demonstrated that it is overex-
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sensitivity to cytochrome c. In fact, microinjecting cyto-
chrome c into these cells causes cell death through an
increased association of caspase-9 to Apaf1 and subsequent
activation of effector caspases (48).
The apoptosome formation is also inﬂuenced by intra-
cellular nucleotides, potassium and calcium concentration.
As regards intracellular nucleotides, it has been demonstrat-
ed that they have an inhibitory role on apotosome in normal
conditions (49, 50). In particular, they bind to the lysine
residues of cytochrome c, so preventing its binding with
Apaf1. In physiological conditions, nucleotide concentration
prevents the mitochondrial release of small quantities of
cytochrome c from activating the apoptosome. However,
under apoptotic stimuli, their concentration decreases, as
observed in previous experiments, so permitting apoptosome
formation (49).
Potassium seems to have a similar role. It has been
demonstrated that normal potassium concentration in the cell
inhibits Apaf1 oligomerization. This effect is antagonized in a
concentration dependent manner by cytochrome c,s ot h e
assembly of the apoptosome requires a massive release of
cythocrome c from mitochondria (51).
Moreover, it has been recently demonstrated that calcium
binds to monomeric Apaf1, so blocking apoptosome assembly
by impeding the nucleotide exchange (52).
PHARMACOLOGICAL APOPTOSIS REGULATION
IN PRECLINICAL AND CLINICAL DEVELOPMENT
Numerous novel approaches are currently being pursued
employing recombinant biomolecules, antisense strategies,
gene therapy or classical organic and combinatorial chemistry
to target speciﬁc apoptotic regulators. All these approaches
aim to correct excessive or deﬁcient cell death in human
diseases or in animal/cellular models of disease.
In general, the upregulation (or downregulation) of anti-
apoptotic proteins leads to a prevention (or induction) of
apoptosis which can be solved through inhibitors (or activa-
tors) able to bind and modify their activity. Hence, there is an
enormous interest in devising therapeutic strategies to
modulate key molecules involved in life–death decision in
the cell. We will focus here on some of these important key
molecules and discuss them as targets in apoptosis-based
therapies at the preclinical and clinical stage.
Bcl-2 as Target of Drug Design
Bcl-2, discovered because of the translocation t (14:18)
present in many patients affected by follicular lymphoma,
was the ﬁrst oncogene to cause cancer inhibiting apoptosis
and not inducing cell proliferation (53). It is overexpressed in
several tumors (54) and is also associated with resistance to
chemotherapy. There are some exceptions where its over-
expression is associated with better prognoses and in other
cases, where its downregulation does not affect tumor
growth. This is probably caused by Bcl-2 involvement in
both apoptosis and cell cycle control (55). Despite this, it
remains a good target for drug design (Table I).
The Bcl-2 family members regulation is not clear and
several models have been proposed (56). According to
rheostat model (57), Bcl-2 family members are involved in
a complex network of direct and indirect interactions. It has
also been proposed that BH3-only proteins, activated in
response to different apoptotic stimuli and characterized
by different afﬁnity for the Bcl-2 pro-apoptotic proteins,
could bind them impeding their inhibitory effect on Bcl-2
anti-apoptotic factors. According to another model, some
BH3-only proteins could act as Bderepressors^ and others
as Bdirect activators.^ Derepressors bind to Bcl-2 anti-
apoptotic proteins, inhibiting them and leaving direct
activators free to interact with Bax and Bak (11). Several
studies are focused on Bcl-2 inhibition, in particular, devel-
oping small molecules and peptides which mimic pro-
apoptotic BH3-only proteins.
Studies using small molecules like HA14-1 (58), antymi-
cin A (59), tetrocarcin A (TCA; 60), chelerythrine, a natural
benzophenanthridine alkaloid, show that they induce apo-
ptosis in cells overexpressing Bcl-2 and Bcl-XL (61), although
a recent study (62) has demonstrated that the mechanism of
action of these compounds (HA14-1, gossypol, chelerythrine
and antymicin A) is independent of Bax and Bak. Therefore
they could not act solely as BH3 mimetics, consequently, the
molecular mechanism by which these reagents induce cell
death remains unclear.
Recent preclinical studies evidenced that gossypol (63),
a lipid soluble polyphenolic constituent of cottonseed oil,
binds to Bcl-XL and, with less afﬁnity, to Bcl-2, causing their
downregulation.
The clinical study (64) investigated the safety and
efﬁcacy of oral gossypol in a heavily pretreated patient
population with metastatic breast cancer. Gossypol is safe,
but demonstrated limited activity in doxorubicin and taxane
refractory metastatic breast cancer. At dosage of 40 mg/day
in divided dose the agent was well tolerated and the toxicities
experienced by this patient population consisted primarily of
mild nausea, fatigue, emesis, and diarrhea. However, no
therapeutic responses were observed. Interestingly, gossypol
appears to affect the expression of Rb protein and cyclin D1
in breast cancer metastases suggesting a potential role for
gossypol as a modulator of cell cycle regulation.
FDA (Food and Drug Administration) approved gossy-
pol for phase I clinical trial (ClinicalTrials.gov idenﬁer
NCT0039043) for patients with newly diagnosed glioblastoma
multiform and for phase II clinical trial (ClinicalTrials.gov
identiﬁer NCT00440388) for patients with diagnosed follicu-
lar lymphoma.
ABT-737, another inhibitor molecule, is more speciﬁc
for Bcl-2 and showed efﬁcacy against small-cell lung carci-
noma (65), lymphoma (66) and myeloma (67). New small
organic inhibitors speciﬁc for Bcl-2 have been recently devel-
oped (68). Epigallocatechin-3-gallate (EGCG), a major con-
stituent polyphenol in green tea extract, was found to have a
pronounced growth inhibitory effect on cancer cells. Many
studies in vitro conﬁrmed that EGCG signiﬁcantly down-
modulates the expression of Bcl-2 family proteins (69–71).
In an initial clinical study (Phase I–II) currently recruit-
ing patients (ClinicalTrials.gov identiﬁer NCT0016635),
healthy volunteers and patients with chronic limphocytic
leukemia are being treated with oral green tea extract. This
clinical trial is for patients with early stage chronic lympho-
citic leukemia who do not require active chemoterapy
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immediately below the level that causes too many side effects
(the best dose); (2) to evaluate effectiveness of the treatment
every month during treatment.
Recently, FDA approved EGCG for phase I clinical trial
(ClinicalTrials.gov identiﬁer NCT00233935, studying the side
effects and best dose of green tea extract in preventing
esophageal cancer in patients with Barrett_s esophagus) and
for phase II clinical trial (www.ClinicalTrials.gov identiﬁer
NCT00303823, studying green tea extract to see how well it
works compared to a placebo in preventing cervical cancer in
patients with human papillomavirus and low-grade cervical
intraepithelial neoplasia).
Another promising technique is the use of antisense
RNAs, which, by binding speciﬁc mRNAs target, cause their
cleavage by RNase-H (72). The antisense Bcl-2 oblimersen, is
an 18-mer phosphorothioate oligonucleotide that binds to the
ﬁrst six codons of the human Bcl-2 mRNA. Several studies
show that the downregulation of Bcl-2 by oblimersen leads to
apoptosis activation (73). The combination treatment with
oblimersen and an anticancer drug increased the chemothera-
peutic effect in some types of tumor (73). In patients with
advanced melanoma, for example, the addition of oblimersen
to dacarbazine (used in therapy for methastatic melanoma)
improved response to this drug without an increasing toxicity.
In this melanoma study (74) the patients with advanced
melanoma have been randomly assigned to treatment with
dacarbazine (1,000 mg/m
2) alone or preceded by a 5-day
continuous intravenous infusion of oblimersen (7 mg kg
j1
d
j1) every 3 weeks for up to eight cycles. The primary endpoint
of this clinical trial was overall survival and the results have
been very promising. The addition of oblimersen to dacarbazine
yielded a trend toward improved survival at 24-month follow-up
and signiﬁcant increases in progression-free survival, overall
response, complete response, and durable response.
In patients with relapsed or refractory chronic lympho-
cytic leukemia (75) the addition of oblimersen to ﬂudarabine
plus cyclophosphamide signiﬁcantly increased the rate of
complete response plus nodular partial responses. These
responses were durable and signiﬁcantly longer than were
those achieved with chemotherapy alone.
We feel obliged to inform the reader that recent papers
have debated the results on oblimersen and Bcl-2 down-
regulation. In fact, Kim et al. (73) demonstrated that the
oblimersen activity is dependent on an immune stimulatory
effect rather than on Bcl-2 downregulation.
Also, Tan et al. (76,77) demonstrated that oblimersen,
induces apoptosis in melanoma and other cancer cells, and this
apoptosis happens before and in the absence of the down-
regulation of Bcl-2 and thus seems to be Bcl-2-independent.
In addition to approaches aimed at downregulating Bcl-2
protein, its selective overexpression might be a valuable
strategy for the protection against premature cell death.
Pioneering work in the area of Bcl-2 upregulation has
been performed in a mouse model of chronic cardiomyopa-
thy and stroke (78–80).
Caspases and Their Regulators
Experimental evidence suggests that inhibition of cas-
pase activity blocks cell death in many models of human
disease, including various neurodegenerative disorders,
stroke, heart attack and liver injury. Therefore, caspase
inhibitors are a promising pharmacological tool providing
treatments for stroke and other human diseases mentioned
above (Table II).
Several caspase inhibitors are currently in the preclinical
stage. The Merck Frosst Center recently developed a small
reversible caspase-3 inhibitor, M-826. In a mouse model of
hypoxia-ischemia M-826 blocked brain tissue damage (81).
Also, in a mouse model of Huntington_s disease, the same
inhibitor prevented striatal neuron death (82).
Even before the discovery of the role of caspases in
apoptosis, several companies started drugs programs aimed
at screening for caspase-1 inhibitors in order to suppress IL-
1b. Consequently we cannot consider the anti-apoptotic
activity of pan-caspase inhibitors without taking into
account their effect on the caspase-1 as anti-inﬂammatory
compounds.
A successful compound which is already in phase II of
clinical studies is the irreversible pan-caspase inhibitor, IDN-
6556 (IDUN Pharmaceuticals). IDN-6556 is considered a
candidate for the treatment of acute-tissue injury disease. In
a ﬁrst clinical study, healthy volunteers and patients with
impaired hepatic function were treated with intravenous
infusion of IDN-6556. Doses up to 1.5 mg/kg for 7 days were
well tolerated. Orally given IDN-6556 is currently being
tested in phase II clinical trials for the treatment of HCV
infection, and further studies are planned for nonalcoholic
steatohepatitis and other hepatobiliar diseases. Vertex/Aven-
tis has developed VX-799, another pan-caspase inhibitor.
VX-799 is one of the ﬁrst small molecule caspase inhibitors to
be advanced into development, and represents a completely
novel approach to treating sepsis patients, for whom limited
treatment options are available. This drug is currently in
phase I of clinical trial.
The activation of caspases, on the other hand, might be a
valuable pharmacological strategy, especially for the therapy
of human cancer. Because the success of gene delivery
approaches is still limited, pharmacological activation of
cellular caspases by small cell-permeable compounds could
provide a more efﬁcient tool for targeting cancer cells.
In several cell types, it was previously shown that soluble
RGD peptides induce apoptosis, which was ﬁrst attributed to
the loss of cell attachment and survival signalling (83,84).
Buckley et al. (85), however, demonstrated that RGD
peptides induce caspase-3 activation independently of integ-
rins. Recently Merck developed a RGD-based candidate
drug to inhibit neo-formation of tumor blood vessels.
Maxim Pharmaceuticals are currently evaluating the
therapeutic potential of a small molecule which activates
caspases, MX-2060, a derivative of gambogic acid, a natural
product extracted from Garcinia hurbury (86) and tested as a
potential anticancer agent in human cancer xenograft animal
models.
Some attempts have also been made to directly intro-
duce caspase-3 into tumoral cells by fusing the protein with
an antibody or by an expression plasmid. Jurkat cells,
transfected with a plasmid encoding caspase-3 fused with an
antibody against an antigen (HER2) widely expressed on the
surface of tumor cells (breast, ovary, stomach carcinoma),
were able to produce and secrete the fusion protein called
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Companies: Aventis (www.aventis.com), Idun Pharmaceuticals, Inc. (www.idun.com), Maxim Pharmaceuticals (www.maxim.com), Merck
Frosst Canada & Co. (www.merck-frosst.ca), Vertex pharmaceuticals, Inc. (www.vpharm.com), Eli Lilly and Company (www.lilly.com), NCI
(National Cancer Institute, www.cancer.gov), NCI of Canada (National Cancer Institute of Canada www.ncic.cancer.ca); Ascenta
Therapeutics (www.ascenta.com); Aegera Therapeutics Inc. (www.aegera.com), Hybridon (www.hybridon.com); Genta Incorporated
(www.genta.com); Kyowa Hakko Kogyo Co., Ltd (www.kyowa.co.jp); ISIS Pharmaceuticals (www.isispharm.com); Hybridon (www.
hybridon.com).
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overexpressing cancer cells; it is internalized, subjected to
lysosomal cleavage and released into the cytosol, where it
leads to cell death. This fusion protein also causes suppres-
sion of HER2-overexpressing tumors in vivo (87). Some
attempts have also been made in order to obtain adenoviral
constructs expressing caspase-3 whose expression in cells was
very effective in inducing apoptosis (88).
In some tumors, caspase activity is prevented by the
overexpression of speciﬁc inhibitors. In particular, XIAP is
overexpressed in some tumors (37), preventing caspase
activity and causing chemoresistance. This makes it one of
the most promising targets in cancer therapy.
Several antisense oligonucleotides speciﬁc for XIAP
mRNA are effective in vitro and some of them are in different
phases of clinical trials. For example, antisense oligonucleotide
AEG35156/GEM 640 (Aegera Therapeutics/Hybridon)
reduces XIAP levels and sensitizes tumors to chemotherapy.
It is undergoing multiple phase I clinical trials in cancer as a
single agent or in combination with other drugs (89).
A clinical study is ongoing (ClinicalTrials.gov identiﬁer
NCT00385775). This study is designed to ﬁnd the maximum
tolerated dose, safety and toxicity proﬁle, and to identify any
dose limiting toxicities of AEG35156 administered in 2-
h infusions to patients with advanced cancers. This is a Phase
I–II, single-arm, open-label, dose escalation study to establish
therecommendeddoseandactivityofAEG35156administered
as an 2-h daily infusion over 3 days initially followed by weekly
2-h intravenous infusions in patients with advanced cancers.
Primary outcome measures of this study is to determine
the dose level at which AEG35156 is well tolerated based
upon development of toxicities during the ﬁrst cycle of
therapy unless cumulative or delayed toxicity is encountered.
Secondary outcome measures of this study is to evaluate: (1)
the impact of AEG35156 on inhibition and apoptosis in
tumor biopsies or circulating tumour cells; (2) the occurrence
of XIAP knockdown in peripheral blood mononuclear cells;
(3) the plasma pharmacokinetic proﬁle of AEG35156; (4) the
possible anti-tumor activity of XIAP.
Recently, FDA approved AEG35156 for phase I clinical
trial (www.ClinicalTrials.gov identiﬁer NCT00372736, study-
ing the side effects and best dose of AEG35156 when given
together with docetaxel in treating patients with locally
advanced, metastatic, or recurrent solid tumors).
The study of XIAP antagonists and the analysis of
structure and function of XIAP domains is also relevant here,
in order to permit the designing or identifying of inhibitor
peptides able to bind a XIAP speciﬁc domain. For example,
it is known that XIAP antagonists, such as Smac/DIABLO
and Omi/Htra2 (90), share the IBM (IAP Binding Motif);
and it is also known that peptides corresponding to the N-
terminal of Smac/DIABLO sensitize lung cancer to cisplatin
and taxol (91). Recently other antagonists have been
identiﬁed, which reside in mitochondria and contain the
IBM (92) and they should be useful for studying XIAP
regulation. Based on these observations, several studies were
switched to obtain Smac/DIABLO peptides or IBM domains
fused with carriers, able to bind and inhibit XIAP and, more
recently, to also obtain speciﬁc inhibitors for BIR2 or BIR3
domains (37). One of the most recent is embelin, a small-
molecular weight inhibitor discovered by screening of a
herbal medicine three-dimensional database (93). Embelin
binds to XIAP BIR3 domain and inhibits cell growth, induces
apoptosis, and activates caspase-9 in prostate cancer cells
with high levels of XIAP (94).
AFP (Alpha-FetoProtein) promotes growth, but it is
also involved in tumor inhibition.
Its role in tumor growth inhibition and suppression has
been observed using a derived AFP-synthetic peptide (96).
However, AFP mechanism of action is still unclear. Some
studies have shown that AFP leads cancer cells, but not
control cells, to death through caspase-3 (95). In a cell-free
system AFP has been demonstrated to facilitate the release
of caspase-3 from the apoptosome, probably displacing
cIAP2 (97). Recently, it has been demonstrated that AFP
penetrates tumor cells, since they express AFP receptors on
their surface, and that it disrupts the association between
XIAP and caspase-3. AFP also binds free XIAP, so impeding
its binding to caspase-3 (98). More studies, not only in vitro,
are required to clarify this aspect.
Survivin is detected in many tumors (99), whereas it is
expressed only in a few adult tissues (100). Even if its role in
direct caspase regulation is unclear, it seems to induce
chemoresistance in tumor cells making it an interesting target
for drug design. The antisense oligonucleotide LY2181308
(ISIS/Eli Lilly), speciﬁc for survivin, is being evaluated in
phase I clinical trials (www.ClinicalTrials.gov Identiﬁer
NCT00415155).
The primary objective of this clinical study, sponsored by
Eli Lilly and Company, will be to estimate the time to
progressive disease for patients with advanced hepatocellular
cancer who receive LY2181308.
Primary Outcome Measures will be: a) the recommen-
ded dose of LY2181308 in the advanced hepatocellular
cancer (HCC) population; b) time to progression for patients
with advanced HCC who have received LY2181308.
Secondary Outcome Measures will be: (a) overall survival
time; (b) progression-free survival; (c) time to progression of
cancer symptoms; (d) safety, response rate, pharmacokinetics,
effect on circulating tumor cells and survivin expression.
Interfering with Apoptosome Formation
As outlined above, Apaf1/caspase-9 apoptosome forma-
tion is a crucial event in the apoptotic cascade. Therefore, the
identiﬁcation of new potential drugs which prevent (or
stabilize) the formation of active apoptosome complex could
be a good strategy for the treatment of diseases characterized
by excessive (or insufﬁcient) apoptosis.
Recently, taurine (2-aminoethanesulfonic acid) has been
found to prevent ischemia-induced apoptosis in cardiomyo-
cytes through its ability to inhibit Apaf1/caspase-9 apopto-
some formation without preventing mitochondrial
dysfunction under ischemic conditions (101). The possible
mechanism by which taurine inhibits the apoptosome forma-
tion was identiﬁed as being capable of reducing the expres-
sion of caspase-9, a fundamental component of apoptosome.
Several active compounds interfering with apoptosome
assembly have been recently identiﬁed by high throughput
screening of a chemical library. In particular, oligomers of N-
alkylglycines also known as peptoids, are an interesting
family of non-natural molecules which exhibit many biolog-
747 The Apoptosome: Emerging Insights and New Potential Targetsical activities. Among these compounds, peptoid 1a binds
reversibly to Apaf1, precluding the recruitment and activa-
tion of procaspase-9 and, consequently, inhibiting the apo-
ptotic cascade (102). Conversely, the possibility of increasing
apoptosome complex formation is relevant in cancer therapy.
To date the studies have been focused in particular on Apaf1
and/or caspase-9 expression levels in several tumors; for
example, it is well-known that Apaf1 gene expression is
a l t e r e di nl e u k e m i ac e l l s( 103), bladder cancer (104),
gastrointestinal tumors (105), glioblastoma (106) and germ
line tumor (107). Moreover, the Apaf1 gene is silenced in
some melanoma cell lines (108) but not in others (109),
probably because of different cell culture conditions, protein
extraction antibody usage, or different sites of origin. In fact,
melanoma is heterogeneous (110).
Some efforts have also been made to restore Apaf1 or
caspase-9 levels. For instance LAQ824, a HDAC (histone
deacetylases deacetylate the nucleosomal histones reducing
gene expression) inhibitor family, causes apoptosis in lung
cancer cells, but not in ﬁbroblasts, promoting, in particular,
mitochondrial pro-apoptotic factor release and also inducing
Apaf1 and caspase-9 transcription (111). Another study was
carried out to ﬁnd a correlation between Apaf1 and caspase-9
levels and chemoterapy resistance. It revealed that there was
not a strong correlation between these proteins levels and
sensitivity to drugs in vitro and that the only role that Apaf1
and caspase-9 levels seemed to have is in slowing down cell
death. (112).
It is important to highlight that some studies suggest that
Apaf1 and caspase-9 have other roles independent of the
apoptosome; therefore, altering their levels could lead to
altering cellular function.
In particular, the evidence that: (a) resectable non-small
cell lung cancers containing high levels of Apaf1 in an
atypical nuclear localization have a favorable prognosis
(113); (b) cisplatin induced translocation of Apaf1 from the
cytoplasm to the nucleus (113); and (c) the nuclear Apaf1
translocation was independent from the apoptosis-related
nuclear permeabilization (114) led us to suppose non-
apoptotic role(s) of Apaf1.
CONCLUSIONS
Emerging knowledge about the proteins that constitute
the apoptotic machinery and the deﬁnition of molecular
structure of the apoptosome complex has revealed new
potential targets for molecular therapy. Despite very encour-
aging experimental data in vitro and even in animal models,
several problems remain to be solved and limit the use of
experimental drugs in clinical practice.
A major pharmacological problem frequently encoun-
tered by the development of brain-active anti-apoptotic drugs
is the relative impermeability of the brain–blood barrier for
caspase inhibitors currently in use. Also, caspase inhibitors
may exhibit activity in vivo, even when they are applied post-
insult. However, in many acute diseases (stroke, heart attack)
pharmacological treatment needs to be available immediate-
ly. The apoptosome, considered as a complex, is an emerging
pharmacological target, even though only few compounds
targeting it have been tested and none of these have yet been
approved by FDA for starting clinical trials.
The discovery of apoptosome inhibitors will provide a
new therapeutical tool for the treatment of apoptosis-
mediated disease. Of particular importance are those new
compounds able to inhibit apoptosome stability and activity,
by acting on intracellular protein–protein interactions with-
out altering the transcriptional levels of the apoptosome
components.
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